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In the disease paroxysmal nocturnal hemoglobinuria (PNH), 1 erythrocytes and 
other  blood elements  have  an  acquired  defect that  renders  them  abnormally 
sensitive to the lytic action of complement. A number of erythrocyte membrane 
abnormalities  have been shown  to be associated with  the  PNH defect: (a) the 
PNH cell's membrane is a better acceptor of activated C3 than is the membrane 
of a normal cell (1); (b) the C3, once deposited on the membrane, is more stable 
than C3 deposited on a normal cell (2, 3); (c) the PNH cell membrane may allow 
more effective insertion  of the late-acting lytic components than do normal cell 
membranes (4). 
Recently, two intrinsic cell membrane proteins have been reported to influence 
the stability of complement enzymes and proteins deposited on normal  human 
erythrocytes.  CR1,  the  receptor for the complement components C4b and/or 
C3b, acts to control the degradation of these important protein fragments when 
deposited on cell surfaces (reviewed in 5 and 6). Recent work has suggested that 
erythrocytes (RBC) from patients with PNH have decreased red cell CR1 (7, 8); 
however,  we  have  reported  a  patient  with  absent  erythrocyte  CR1  without 
evidence of a  PNH-like red cell defect (8).  A  second protein,  DAF, originally 
described as a factor accelerating the decay of the classical pathway C3 convertase, 
recently has been found to accelerate the destruction of the alternative pathway 
convertase as well (8). Work from two laboratories has suggested that this protein 
is partially  or completely absent from  the  membranes of PNH  RBC (8,  9).  A 
total of three patients  has been reported with absent DAF in  their  PNH RBC 
population.  In addition, antibody to this protein has been reported to induce a 
PNH-like abnormality of normal cells (8). Defective regulation of the membrane- 
bound convertase would at least partly explain the abnormal sensitivity of PNH 
RBC to complement-mediated lysis. 
J  Abbreviations used in this paper: BFU-E, erythroid burst-forming cell; CFU-E, late erythroid 
colony-forming cell; DAF, decay-accelerating  factor; FACS, fluorescence-activated  cell sorter; PBS, 
phosphate-buffered saline; PNH, paroxysmal nocturnal hemoglobinuria; RBC, red blood cell. 
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TABLE  [ 
Clinical Status of PNH Patients 
Percent  Percent  Percent 
Patient  Age  Sex  Status  BM  PNH  DAF- 
cellularity  RBC  RBC 
3  33  F  Moderate pancytopenia  80  33  43 
4  40  M  Mild thrombocytopenia; re-  40  17  40 
current hemolytic crises 
10  34  M  Mild hemolysis; androgen Rx  75  28  29 
14  30  F  Moderate pancytopenia  70  22  10 
15  26  M  Moderate pancytopenia; re-  70  37  44 
current hemolytic crises; 
steroid Rx 
17  26  M  Recovered aplastic anemia;  10  19  21 
mild pancytopenia 
Patient numbers refer to a  larger series of individuals with PNH to be reported.  ~ All patients had 
positive Ham tests. PNH RBC were determined spectrophotometrically.  DAF- RBC were determined 
using a specific anti-DAF antiserum and flow microfluorometry. 
We used a  specific antiserum to DAF to study the generation of cells lacking 
DAF  during  erythropoiesis.  DAF  expression  was  measured  on  the  erythroid 
progenitors, their in vitro progeny normoblasts, and the circulating RBC of the 
PNH patients. 
Materials and  Methods 
Patients  and  Controls.  The  clinical  and  laboratory  features  of the  patients  in  the 
current  study  are  described  elsewhere  ~ and  the  corresponding  patient  identification 
numbers are used here. All six patients (Table I) had a positive Ham test, and variable 
proportions of PNH cells could be measured in the circulation by a quantitative, spectro- 
photometric analysis of complement lysis  (10).  All  patients showed evidence of either 
chronic or recurrent episodes of hemolysis or bone marrow failure manifested by pancy- 
topenia.  At  the  time of study one  patient was receiving corticosteroids, and another, 
anabolic  steroids;  four  patients  were  untreated.  Studies  were  reproduced  in  part  on 
separate occasions in two of the cases studied.  Individuals who served as controls were 
normal volunteers. Protocols for obtaining blood and bone marrow from patients and 
volunteers were approved by the National Heart, Lung, and Blood Institute institutional 
review board. 
Tissues.  Peripheral blood was collected in preservative-free heparin (Forest Pharma- 
ceuticals,  Inc., St.  Louis,  MO),  1,500  U/30  ml.  Bone  marrow was aspirated from the 
posterior  iliac  crest  directly  into  syringes containing  1.5  ml  Iscove's modification  of 
Dulbecco's medium with 100 U/ml of heparin or, in some cases, into 1.5 ml of EDTA in 
phosphate-buffered saline (PBS) to a  final concentration of 10 raM.  Mononuclear cells 
were isolated by density gradient sedimentation on  Ficoli  (Lymphocyte Separation Me- 
dium; Litton Bionetics, Inc., Charleston, SC). 
Erythroid  Colony Cultures.  Bone marrow mononuclear cells were cultured  to detect 
the primitive erythroid progenitor,  the erythroid burst-forming cell  (BFU-E),  and  the 
more mature progenitor, the erythroid colony-forming cell (CFU-E), in methylcellulose 
as described.2 C F U-E-derived colonies were recognized by their characteristic morphology 
at day  8;  BFU-E-derived bursts  consisted  of a  minimum of three  clusters at  day  18. 
Erythroid colonies were removed from culture using a 10 #1 voi micropipette or a tapered 
Pasteur pipette. 
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Flow Microfluorometry.  Flow microfluorometric analysis  was performed on three dif- 
ferent cell populations: peripheral blood erythrocytes, bone marrow mononuclear cells, 
and normoblast progeny in colonies removed from methylcellulose cultures. The charac- 
teristics of rabbit anti-DAF antibody used in these studies have been reported elsewhere 
(8). The antiserum recognizes a 73,000 moi wt structure on all normal RBC that represents 
the DAF molecule. Binding of this antiserum renders normal red blood cells PNH-iike, 
making them susceptible to lysis by acidified serum. The antiserum was  first absorbed 
with PNH RBC membranes from patient 3 to remove the minor contaminating antibody 
specificity directed against the complement receptor CRI.  The fluorescein-conjugated 
mouse anti-rabbit IgG (HyCIone Laboratories, Logan, UT) was repeatedly absorbed with 
normal peripheral blood red cells to reduce nonspecific binding.  RBC (2 ×  107 to 6  × 
107), bone marrow mononuclear cells (4 ×  106), or individual bursts (150-60,000+ cells 
per colony) were incubated with anti-DAF diluted 1:10 in PBS for 30 rain at 4 ° C, washed 
twice in PBS, and incubated with anti-rabbit IgG at optimal concentrations, followed by 
two final washes and suspension in PBS.  Erythrocytes were analyzed and bone marrow 
mononuclear cells were analyzed and sorted using a  fluorescence-activated cell sorter 
(FACS  II;  Becton  Dickinson  Immunocytometry Systems,  Mountain  View,  CA).  For 
technical reasons, the small  numbers of cells that constituted mature erythroid colonies 
were analyzed using an Epics V (Coulter Electronics, Hialeah, FL). 
Erythroid progenitor cells have been reported to lack Fc receptors (11). In confirmation 
of these findings, we found that an undetectable number of bone marrow mononuclear 
cells bound aggregated human IgG and fluoresceinated anti-human IgG (data not shown). 
To control for nonspecific binding of  rabbit antibodies, human bone marrow mononuclear 
cells from patient 14 were incubated with an irrelevant rabbit antiserum and fluorescein- 
ated anti-rabbit IgG, sorted by flow cytometry, and the antibody-binding and -nonbinding 
fractions cultured for the presence of erythroid progenitors. No hematopoietic colony- 
forming cells were  found in  the  positive fraction of cells  (data not  shown).  In  other 
experiments,  the  same  cell population  incubated  with  fluoresceinated antibody alone 
served as a control. 
Results 
Detection of  DAF- RBC in PNH Blood.  To determine cell surface DAF expres- 
sion, RBC were incubated with a specific rabbit antiserum to DAF followed by a 
fluoresceinated  anti-rabbit  IgG  antibody  and  analyzed  using  a  FACS.  Two 
discrete populations of RBC were detected in all six patients with PNH (Fig.  1, 
A  and  C).  The  less  fluorescent population  of DAF-  cells  coincided  with  the 
negative control consisting of RBC  exposed to the second antibody only (Fig. 
1 F).  In  contrast,  a  single,  DAF  + population  of RBC  was  observed  in  normal 
blood (Fig.  1 E). 
Relationship  of Absence of DAF to Complement Sensitivity.  The amount of im- 
munoprecipitated DAF has been correlated with the relative sensitivity of differ- 
ent populations of PNH RBC (9). To test the relationship between the absence 
of DAF and the sensitivity of RBC to lysis in acidified serum, we measured the 
size of the DAF  + and DAF- RBC populations before and after complement lysis 
(Figs.  1 and 2). In all patients tested, incubation in acidified serum under optimal 
conditions for lysis of PNH cells resulted in reduction in the proportion of DAF- 
cells;  the  average  reduction  in  relative  DAF-  populations  was  52  +  5%,  as 
calculated from the respective ratios of negative cells. In no case was the DAF- 
population completely eliminated by prior acidified serum treatment. 
DAF Expression of Erythroid Progenitor Cells.  A  variable proportion of PNH 
bone marrow cells was DAF- (25-79%, x _+ SEM =  40 -_+ 11%; normal range, 5- 
20%, x +  SEM =  9 +  5%). As hematopoietic stem cells are extremely infrequent MOORE  ET  AL. 
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FIGURE  I.  DAF  expression on  erythrocytes.  Erythroyctes  were  incubated with a  specific 
rabbit antiserum to  DAF followed by a  fluoresceinated anti-rabbit IgG antibody, and then 
analyzed by flow microfluorometry (see Materials and Methods). Two discrete populations of 
red cells were detected  in all six  PNH  patients; data  from  two  representative patients are 
shown in A and C. The population of DAF- cells coincided with the negative controls consisting 
of red cells exposed only to the second antibody (E).  Incubation of the patients' red cells in 
acidified serum before analysis reduced the DAF- population (B, D). A single DAF  + population 
of RBC was observed in normal blood (F). 
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FIGURE  2.  Relationship  of  the  absence  of  DAF  to  complement  sensitivity.  To  test  the 
relationship between the absence of DAF and the sensitivity of red cells to lysis  in acidified 
serum, the DAF  + and DAF- RBC populations were measured before and after complement- 
mediated lysis. Data from six patients studied have been plotted schematically; patient numbers 
are shown in parentheses.  Incubation in heat-treated serum did not alter the proportion of 
DAF- cells (data not shown). 1186  DAF  LOSS  DURING  PNH  ERYTHROPOIESIS 
in the bone marrow, we tested for the presence of DAF on erythroid progenitors 
using the FACS.  PNH  and normal bone marrow mononuclear cells labeled with 
anti-DAF  were  separated  by flow microfluorometry,  and  the  DAF  + and  DAF- 
populations  each  cultured  in  methylcellulose  for  the  detection  of  erythroid 
colonies.  All erythroid colonies were grown from the DAF  + populations of both 
normal  and  PNH  bone  marrow  mononuclear  cells,  indicating  that  the  BFU-E 
and CFU-E progenitor cells expresed  the DAF antigen (Table  II). 
DAF  Expression  on  Normoblasts  that  Develop  In  Vitro.  Failure  to  detect  a 
discrete  population  of DAF-  erythroid  progenitors  in  PNH  bone  marrow  sug- 
gested that DAF might be lost during erythroid differentiation.  To test for this 
possibility,  individual  bursts,  representing  the  progeny  of a  single  erythroid 
progenitor  cell,  were  removed  from culture  and analyzed  for DAF  expression 
(Fig.  3, Table  III). The  mature erythroid progeny of bursts grown from normal 
bone  marrow  were  a  single  population  of DAF  +  cells  (Fig.  3E).  In  contrast, 
normoblasts  from  PNH  bursts  showed  two discrete  populations  of cells  by the 
criterion of DAF positivity, and most cells were DAF-. Of the total progeny cells 
in  three  PNH  patients  analyzed,  79  ___  4%  were  DAF-.  Only  3  of 27  bursts 
analyzed,  one in each patient,  showed >50%  DAF  + or normal cells.  The  occur- 
rence  of DAF-  progeny  in  colonies  derived  from  DAF  + progenitors  indicated 
TABLE  II 
DAF Expression on Erythroid Progenitors 
Patients  Progenitor 
Colonies per 105 
mononuclear ceils 
DAF  +  DAF- 
10  CFU-E  41  0 
BFU-E  3  0 
14  CFU-E  17  0 
BFU-E  7  0 
15  CFU-E  29  0 
BFU-E  23  0 
17  CFU-E  89  0 
BFU-E  20  0 
Normals 
1  CFU-E  146  0 
BFU-E  116  0 
2  CFU-E  92  0 
BFU-E  87  0 
Bone marrow mononuclear cells were separated  by a FACS after labeling 
with anti-DAF antiserum and fluorescein isothiocyanate-conjugated  anti- 
rabbit lgG.  The DAF  ÷ and DAF- cells were plated  in methylcellulose  to 
determine the proportion of erythroid progenitors (BFU-E and CFU-E) 
in each population. To control for loss during sorting experiments,  colo- 
nies obtained were compared to cultures of unsorted cells for each of the 
persons tested and there was no significant difference (recovery was 94 -+ 
11%). MOORE  ET  AL. 
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FIGURE 3.  DAF expression or normoblasts that develop in vitro. Individual bursts, containing 
mature normoblasts, were removed from methylcellutose culture of bone marrow mononuclear 
cells on day  18 using a  10-#1 micropipette and incubated with a  specific antiserum to DAF, 
followed by a fluoresceinated anti-rabbit lgG, and then analyzed for DAF expression by flow 
microfluorometry. A  representative burst from a  normal person contains mostly DAF  + cells 
(E).  The  small number of apparently  DAF-  in  the  normal  burst are  probably artifactual, 
resulting from  the inability to completely remove methylcellulose by washing of this small 
number of cells. In contrast, the normoblasts within individual bursts in PNH  patients were 
mostly DAF- (A, B, C, D), corresponding to cells exposed to second antibody alone (F). 
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that DAF expression had been lost, and this PNH characteristic acquired, during 
in vitro erythropoiesis. 
The  RBC of patients  with  the  rare  hematologic  disorder  termed  HEMPAS 
(hereditary  erythroblastic  multinuclearity  with  positive  acidified  serum  test) 
resemble PNH RBC in their sensitivity to antibody-mediated lysis by complement. 
However, in contrast to DAF expression on cells from patients with PNH, DAF 
expression  on  HEMPAS  RBC,  bone marrow  mononuclear  cells,  and  progeny 
normoblasts in vitro was normal (data not shown). 
Discussion 
In  these studies we have  used flow microfluorometry in  combination  with a 
highly specific polyclonal anti-DAF antibody to precisely quantitate  the expres- 
sion  of DAF  on  circulating  RBC,  bone  marrow  mononuclear  cells,  erythroid 
progenitors, and their in vitro progeny.  Blood samples from normal individuals 
showed only DAF  + (or normal) RBC. The DAF- RBC were partially eliminated 
by prior incubation with acidified serum, confirming the abnormal sensitivity of 1188  DAF  LOSS  DURING  PNH  ERY'THROPO1ESIS 
TABLE  III 
DAF Expression on Normoblasts from Individual Bursts 
Percent PNH  Percent normal 
DAF  + (No. of  DAF  + (No. of 
cells)  cells) 
Patient 4  5 (1,829)  Normal 1  71 (3,170) 
9 (1,428)  80 (1,339) 
12 (2,242)  84 (7,806) 
20 (595)  86 (23,028) 
21 (542)  89 (57,656) 
21 (3,120)  96 (805) 
24 (489) 
26 (2,448) 
33 (2,487) 
83 (io,ooo+) 
x-SEM  25+7%  84_+3% 
n  10  6 
Patient  14  9  Normal 2 
11 
24 
31 
33 
33 
64 
73 
81 
89 
x +  SEM  19 _+ 7% 
n  7 
81 _+ 8% 
2 
Patient  17  3 (3,026)  Normal 3 
3 (19,274) 
4 (1,027) 
7 (2,964) 
8(1,158) 
10 (289) 
14(1,161) 
15 (256) 
18 (188) 
57 (939) 
68 (714) 
72 (2,545) 
73 (4,203) 
82 (4,203) 
x +  SEM  14-  5%  73 -+ 3% 
n  10  4 
Mature erythroid bursts were removed from methylcellulose culture and 
subjected to flow microfluorometry after staining with anti-DAF antiserum 
and anti-rabbit  IgG fluorescein isothiocyanate.  Results in three patients 
and three concurrent normal controls are expressed as the proportion of 
DAF  + ceils in each burst tested; shown in parentheses are the number of 
normal blasts  in each burst. 
DAF-  cells to acid hemolysis.  The  resistance  of some  DAF-  RBC  to complement 
|ysis  might  be  due  to  suboptimal  conditions  for  complement-mediated  lysis  or 
may  reflect  the  presence  of other  fluid  phase  or  RBC  membrane-bound  regu- 
latory  mechanisms. MOORE ET  AL.  1189 
DAF was also found expressed on all of the bone marrow mononuclear cells 
of normal individuals.  In the PNH patients,  both DAF  + and DAF- populations 
of mononuclear cells were found in the bone marrow (DAF- PNH marrow cells, 
x +  SEM  =  40  -+  11%;  9  +  5%).  Surprisingly,  all  of the erythroid progenitor 
cells from both normals and PNH patients, as detected by clonogenic and highly 
specific colony assays, were present in the DAF  + population, and therefore the 
erythroid progenitor cell in PNH was phenotypically normal by the criterion of 
DAF  expression.  The  normoblast  progeny  obtained  by  in  vitro  culture  of 
erythroid progenitor  cells from normal  individuals  were mostly DAF  + by flow 
microfluorometric  analysis.  However, unlike the  in  vitro findings  with normal 
individuals, the phenotypically normal progenitors from PNH patients gave rise 
to mostly DAF- or PNH-type normoblasts.  Therefore, loss of DAF and acquisi- 
tion of this PNH-associated defect were shown to be developmental phenomena. 
A residual normal population of erythroid progenitors may have been indicated 
by the single near-normal  burst, containing  mostly DAF  + normoblasts,  in each 
patient. 
Our  results  using  DAF  as a  marker  of the  PNH phenotype  during  in  vitro 
erythropoiesis confirm  our earlier  experiments  using acidified serum  lysis, z In 
those  studies,  unlike  Dessypris  et  al.  (12),  we  were  unable  to  detect  a  large 
proportion  of hematopoietic  progenitors  in  PNH  bone  marrow  susceptible to 
acidified  serum  or  isotonic  sucrose  lysis.  Analogous  to  the  results  with  DAF 
expression, experiments using complement-mediated lysis showed that erythroid 
progenitors  that  do not lyse in acidified serum give rise in vitro to normoblast 
progeny that are abnormally susceptible to complement lysis. Therefore, by both 
the DAF phenotype and the functional complement sensitivity defect, phenotyp- 
ically  normal  progenitor  cells  from  PNH  bone  marrow  generate  PNH-type 
progeny cells in vitro. 
The loss of DAF and acquisition of complement sensitivity during erythropoi- 
esis by PNH progenitor cells is analogous to a few previously described alterations 
in  cell  function  and  membrane  phenotype  detectable  in  vitro.  For  example, 
synthesis of fetal  hemoglobin  as the  major globin  species is a  capacity of cells 
derived from the  more primitive erythroid progenitor,  the  BFU-E, and  not of 
normoblasts  grown  from  the  later  progenitor,  the  CFU-E (13).  Similarly,  the 
HLA-DR antigen  is expressed on BFU-E but is not present on CFU-E or more 
mature  erythroid  cells (14).  However, the  loss during  differentiation  of a  cell 
surface  marker  and  related  functional  capacity  in  association  with  a  specific 
disease is, thus far, unique to PNH. 
Only one burst of ~ 10 analyzed in each PNH patient contained mainly normal 
or DAF  + progeny.  In  the patients'  blood, however, the majority of RBC were 
normal,  with  PNH  cells  representing  17-37%  of the  total  cells.  Thus,  the 
proportion of PNH RBC detected in the circulation of patients was always much 
lower  than  the  proportion  in  the  bone  marrow,  presumably  reflecting  the 
selective destruction in the bone marrow of both mature and immature erythroid 
cells, perhaps by a complement-mediated mechanism. These results are consistent 
with a  model in which all the erythroid progenitors in  PNH are phenotypically 
normal by the criteria of DAF positivity and resistance to complement, but only 
a minority (-10%) are genotypically normal,  as reflected by their ability to give 1190  DAF  LOSS  DURING  PNH  ERYTHROPOIESIS 
rise to entirely normal progeny. The genotypically abnormal PNH cells produce 
the  majority  of progeny  in  tissue  culture,  either  because they  have a  growth 
advantage or, more likely, because their progeny are not lysed as they are in the 
bone marrow of a patient. The patient's erythron, therefore, may be dependent 
for  maintenance  on  a  normal  stem  cell  pool  of very limited  size.  In  another 
report, 2 we measured very low numbers of progenitor cells and also a remarkably 
high  cell  cycling rate  of PNH bone marrow  BFU-E, even  in  comparison  with 
other hemolytic diseases. The demands placed on normal  progenitor cells indi- 
cated  by this  rapid  turnover  and  small  pool  size  may  provide  the  laboratory 
explanation for the close clinical relationship between PNH and aplastic anemia. 
Based on  studies  of a  limited  number  of PNH  patients  heterozygous at  the 
G6PD locus (15,  16),  the generation  of the  PNH population  of RBC has been 
characterized  as clonal.  Our  data clearly do not contradict such a  somatic cell 
genetic defect. In other clonal erythropoietic disorders, the presence of function- 
ally distinct  red  cell  populations  also has  not correlated  with  similarly  distinct 
populations of progenitor cells. For example, individual primitive erythroid stem 
cells in polycythemia vera generate  both erythropoietin-independent  as well as 
normally  erythropoietin-dependent  progeny (17).  Studies  of DAF synthesis in 
developing erythroid cells should permit a more precise localization of the defect 
in PNH cells and perhaps allow modulation of DAF expression both in vitro and 
in vivo. 
Summary 
A glycoprotein that regulates the deposition of C3b on the erythrocyte surface, 
called decay-accelerating factor or DAF, is absent from the red blood cells (RBC) 
of patients with paroxysmal nocturnal hemoglobinuria (PNH), explaining in part 
their abnormal sensitivity to complement. We used a specific antiserum to DAF, 
flow microfluorometry,  and clonogenic assays for erythroid progenitor  cells to 
study PNH erythropoiesis in vitro. By fluorescence-activated cell sorter analysis, 
all RBC from normal individuals are DAF  +. In contrast,  the RBC of six patients 
with PNH showed discrete populations of DAF- cells (10-44%; x +  SEM =  31 
_+  6%).  The  DAF-  RBC  population  was  partly  eliminated  by prior  acidified 
serum lysis.  To determine  whether erythropoietic progenitors expressed DAF, 
bone  marrow  cells  were  sorted  by  flow  microfluorometry  and  the  separated 
DAF  + and DAF- populations then cultured in vitro.  In two normal  individuals, 
but also in six patients with  PNH, erythroid colonies formed only from cells in 
the DAF  + fraction.  However, a variable proportion of the normoblast progeny 
of these DAF  + progenitor cells from patients with PNH was DAF-.  Individual 
bursts removed from cultures of PNH bone marrow showed two discrete popu- 
lations by fluorescence; the majority of normoblasts were DAF-,  only 3  of 27 
individual bursts bad >50% DAF  + cells, and in three patients, DAF- normoblasts 
averaged  79%.  In  contrast,  the  progeny  of  individual  bursts  from  normal 
individuals comprised a  unimodal  DAF  + population.  In each PNH patient,  one 
normal  burst  (>80%  DAF  +  normoblasts)  was  detected,  possibly  reflecting  a 
normal  residual  population  of erythroid  progenitors.  By the criterion  of DAF 
expression, there was no evidence of separate populations of normal and  PNH MOORE  ET AL.  1191 
type progenitor cells. The phenotypically normal erythroid progenitors of PNH 
bone marrow acquire the PNH characteristics during differentiation in vitro. 
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